SUPN — Supernus Pharmaceuticals Balance Sheet
0.000.00%
- $2.70bn
- $2.42bn
- $661.82m
- 88
- 27
- 99
- 83
Annual balance sheet for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 423 | 340 | 461 | 255 | 454 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 141 | 149 | 165 | 144 | 142 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 630 | 602 | 734 | 493 | 686 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 58.1 | 52.3 | 44.1 | 42.5 | 36 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,504 | 1,689 | 1,703 | 1,278 | 1,368 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 245 | 315 | 688 | 290 | 292 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 759 | 873 | 816 | 356 | 332 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 745 | 816 | 886 | 922 | 1,036 |
| Total Liabilities & Shareholders' Equity | 1,504 | 1,689 | 1,703 | 1,278 | 1,368 |
| Total Common Shares Outstanding |